Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients
Abstract
Purpose of review: To provide an overview of the current epidemiology of resistant bacterial infections in hematopoietic cell transplant (HCT) recipients, evaluate recent outcome data, and discuss available treatment strategies in this population.
Recent findings: Recent studies report an increasing incidence of infections caused by multidrug-resistant bacteria among HCT recipients, with marked geographical variability and a significant impact on morbidity and mortality. Several novel agents, including new β-lactam/β-lactamase inhibitors and cefiderocol, have expanded treatment options for resistant Gram-negative infections. However, most evidence supporting their efficacy derives from studies conducted in the general population, as immunocompromised and HCT patients are frequently underrepresented in clinical trials.
Summary: In recent years, growing real-world and observational data have become available specifically in immunocompromised patients, supporting treatment approaches largely consistent with those recommended for the general population, while highlighting important clinical considerations, such as empirical therapy in patients at risk for resistant infections. Ceftolozane-tazobactam is a preferred option for difficult-to-treat Pseudomonas aeruginosa , with combination therapy reserved for selected severe cases. Cefiderocol should be considered in specific scenarios, particularly infections caused by susceptible metallo-β-lactamase-producing organisms. For…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.